43,873 Shares in Bicycle Therapeutics plc (NASDAQ:BCYC) Bought by EntryPoint Capital LLC

EntryPoint Capital LLC purchased a new position in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 43,873 shares of the company's stock, valued at approximately $614,000. EntryPoint Capital LLC owned approximately 0.06% of Bicycle Therapeutics at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Westfield Capital Management Co. LP grew its holdings in Bicycle Therapeutics by 21.5% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,850,945 shares of the company's stock worth $41,887,000 after acquiring an additional 327,089 shares in the last quarter. Candriam S.C.A. raised its stake in Bicycle Therapeutics by 3.5% in the fourth quarter. Candriam S.C.A. now owns 1,087,876 shares of the company's stock worth $15,230,000 after buying an additional 37,278 shares in the last quarter. Point72 Asset Management L.P. raised its stake in Bicycle Therapeutics by 1,438.1% in the third quarter. Point72 Asset Management L.P. now owns 899,799 shares of the company's stock worth $20,362,000 after buying an additional 841,299 shares in the last quarter. Principal Financial Group Inc. bought a new stake in Bicycle Therapeutics during the 3rd quarter valued at $10,028,000. Finally, Platinum Investment Management Ltd. increased its holdings in shares of Bicycle Therapeutics by 13.6% in the 4th quarter. Platinum Investment Management Ltd. now owns 309,059 shares of the company's stock valued at $4,327,000 after acquiring an additional 36,910 shares during the period. Hedge funds and other institutional investors own 86.15% of the company's stock.

Insider Buying and Selling

In other Bicycle Therapeutics news, COO Alistair Milnes sold 4,578 shares of Bicycle Therapeutics stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total transaction of $64,504.02. Following the transaction, the chief operating officer now directly owns 100,724 shares of the company's stock, valued at $1,419,201.16. The trade was a 4.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Travis Alvin Thompson sold 2,686 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $15.00, for a total transaction of $40,290.00. Following the completion of the sale, the chief accounting officer now directly owns 32,146 shares of the company's stock, valued at approximately $482,190. This trade represents a 7.71 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 27,677 shares of company stock worth $392,413. 8.50% of the stock is owned by corporate insiders.

Bicycle Therapeutics Stock Down 2.4 %

Shares of Bicycle Therapeutics stock traded down $0.22 during trading hours on Friday, reaching $8.97. 278,673 shares of the company's stock were exchanged, compared to its average volume of 395,137. The business has a fifty day moving average of $11.32 and a two-hundred day moving average of $17.52. The company has a market capitalization of $620.74 million, a P/E ratio of -2.73 and a beta of 1.12. Bicycle Therapeutics plc has a 1 year low of $8.60 and a 1 year high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.10. The company had revenue of $3.70 million during the quarter, compared to analysts' expectations of $5.47 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. Bicycle Therapeutics's revenue was down 30.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.16) EPS. As a group, research analysts predict that Bicycle Therapeutics plc will post -3.06 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Needham & Company LLC reaffirmed a "buy" rating and set a $30.00 price objective on shares of Bicycle Therapeutics in a research report on Tuesday, March 11th. HC Wainwright reaffirmed a "buy" rating and issued a $33.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, February 26th. B. Riley decreased their target price on Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating for the company in a report on Friday, December 13th. Stephens reaffirmed an "equal weight" rating and issued a $15.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd. Finally, JMP Securities dropped their price objective on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating on the stock in a research note on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $29.14.

Bicycle Therapeutics Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.